Publications by authors named "E Lemieux-Blanchard"
Article Synopsis
- Plasma cell leukemia (PCL) is a rare and aggressive blood cancer with two forms: primary (pPCL) and secondary (sPCL), but information on it is limited due to its low incidence.* -
- A study involving 99 patients found that pPCL has a significantly better survival rate and progression-free survival compared to sPCL, which shows very short survival times and tends to arise from high-risk multiple myeloma cases.* -
- The research indicates no improvement in survival rates for PCL over time and emphasizes the critical need for better treatment strategies to address this serious condition.*
Amyloidosis is a rare protein misfolding disease caused by the accumulation of amyloid fibrils in various tissues and organs. There are different subtypes of amyloidosis, with light chain (AL) amyloidosis being the most common. Amyloidosis is notoriously difficult to diagnose because it is clinically heterogeneous, no single test is diagnostic for the disease, and diagnosis typically involves multiple specialists.
View Article and Find Full Text PDFBackground: Immunoglobulin light chain (AL) amyloidosis is a complex disease marked by a poor clinical portrait and prognosis generally leading to organ dysfunction and shortened survival. We aimed to review the available evidence on whether AL amyloidosis can lead to malnutrition, thus having a negative impact on quality of life (QoL) and survival.
Materials: We searched Pubmed for studies that assessed malnutrition in amyloidosis patients, with no restrictions to the year of publication or language.
Despite novel drugs and autologous HCT, MM remains incurable, with short survival in patients with poor biological characteristics. Allo HCT may be curative in some patients but is hampered by high rates of toxicity and relapse. We hypothesized that bortezomib (BTZ), with its anti-myeloma and immunologic properties, could improve PFS and cGVHD after allo HCT in newly diagnosed MM patients.
View Article and Find Full Text PDFMedulloblastoma is an aggressive primary brain tumor that is extremely rare in adults; therefore, prospective studies are limited. We reviewed the information of all MB patients treated at the CHUM between 2006 and 2017. We divided our cohort by age and further divided adult patients (53%) in two groups, those diagnosed between 2006-2012 and 2013-2017.
View Article and Find Full Text PDF